Sign in

RVP on NYSE

RETRACTABLE TECHNOLOGIES INC

RETRACTABLE TECHNOLOGIES INC is an American surgical and medical instruments and apparatus company.1 It is headquartered in Little Elm, Texas.1 Its shares trade on NYSE under the symbol RVP.1

Price unavailable

Last updated Oct 21, 2026.

Overview

Compare with UTAH MEDICAL PRODUCTS INC, INTERPACE BIOSCIENCES, INC. or Cytosorbents, or pick any stock.

  • TickerRVP on NYSE1
  • IndustrySurgical & Medical Instruments & Apparatus1
  • HeadquartersLittle Elm, Texas1
  • Incorporated inTX2
  • Business address511 Lobo Lane, Little Elm, Tx 75068-00092
  • Filer categoryNon-accelerated filer, Smaller reporting company2

See how the biggest companies compare on our leaderboards

Retractable Technologies, Inc. was incorporated in Texas in 1994. Our business is the manufacturing and marketing of safety medical products (predominately syringes) for the healthcare industry. We have manufacturing facilities in Little Elm, Texas and use manufacturers in China as well. Our syringes are well-suited for administering vaccinations.3 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

0.1%Gross margin4
-55.3%Operating margin4
-32.8%Net margin4
15.8%Revenue growth, 20254
-16.9%Return on equity4
0.01×Debt to equity4

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Products and services

Syringes brought in 65% of the revenue RETRACTABLE TECHNOLOGIES INC broke down this way in fiscal 2025.

  1. Syringes$24.9M465%up 10% from 2024
  2. EasyPoint Needles$11.9M431%up 33% from 2024
  3. Blood Collection Products$1.4M44%down 4% from 2024
  4. Other Products$43.6K40%down 5% from 2024
Products and services by year
Products and services202320242025
Syringes$34.2M$22.6M$24.9M
EasyPoint Needles$7.2M$8.9M$11.9M
Blood Collection Products$1.9M$1.4M$1.4M
Other Products$266.3K$45.9K$43.6K

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue98¢$38.2M
  • Research and development2¢$675.6K
  • Income tax1¢$291.3K

Out of $38.3M in revenue.4 The company lost money this year.

Financial statements

Revenue56784$38.3M in 2025−8% since 2019
0$50.0M$100.0M$150.0M$200.0M2019: $41.8M$41.8M20192020: $81.9M$81.9M2020+96%2021: $188.4M$188.4M2021+130%2022: $94.8M$94.8M2022−50%2023: $43.6M$43.6M2023−54%2024: $33.0M$33.0M2024−24%2025: $38.3M$38.3M2025+16%
Gross profit56784$47.0K in 2025−100% since 2019
-$25.0M0$25.0M$50.0M$75.0M$100.0M2019: $14.1M$14.1M20192020: $37.0M$37.0M2020+162%2021: $95.4M$95.4M2021+158%2022: $28.3M$28.3M2022−70%2023: $9.1M$9.1M2023−68%2024: -$1.0M-$1.0M20242025: $47.0K$47.0K2025
Operating income56784-$21.2M in 2025
-$25.0M0$25.0M$50.0M$75.0M2019: $3.0M$3.0M20192020: $24.1M$24.1M2020+710%2021: $72.6M$72.6M2021+202%2022: -$853.0K-$853.0K20222023: -$11.5M-$11.5M2023+1247%2024: -$21.1M-$21.1M2024+84%2025: -$21.2M-$21.2M2025+0%
Net income56784-$12.6M in 2025
-$20.0M0$20.0M$40.0M$60.0M2019: $3.1M$3.1M20192020: $24.2M$24.2M2020+669%2021: $56.1M$56.1M2021+131%2022: $5.1M$5.1M2022−91%2023: -$7.0M-$7.0M20232024: -$11.9M-$11.9M2024+70%2025: -$12.6M-$12.6M2025+6%

Every line of the income statement as filed: the last 3 fiscal years, latest first.4

Period ending2025-12-312024-12-312023-12-31
Sales, net$38.3M$33.0M$43.6M
Total cost of sales$38.2M$34.1M$34.5M
Gross profit (loss)$47.0K-$1.0M$9.1M
Sales and marketing$6.8M$5.8M$5.7M
Research and development$675.6K$673.9K$581.2K
General and administrative$12.8M$13.6M$14.3M
Impairment of assets$954.4K
Total operating expenses$21.2M$20.1M$20.6M
Loss from operations-$21.2M-$21.1M-$11.5M
Other income - TIA$6.0M$5.9M$6.2M
Unrealized gain (loss) on debt and equity securities-$5.0M$10.8M-$10.5M
Gain on trading debt and equity securities$5.6M$5.6M
Litigation proceeds$1.9M
Interest and other income$547.4K$1.0M$1.4M
Interest expense-$87.9K-$122.5K-$152.2K
Net loss before income taxes-$12.3M-$3.5M-$8.9M
Provision (benefit) for income taxes$291.3K$8.4M-$1.9M
Net loss-$12.6M-$11.9M-$7.0M
Preferred Stock dividend requirements-$230.4K-$230.4K-$231.9K
Net loss applicable to common shareholders-$12.8M-$12.1M-$7.2M
Basic loss per share-$0.43-$0.40-$0.24
Diluted loss per share-$0.43-$0.40-$0.24
Basic (in shares)29.9M shares29.9M shares29.9M shares
Diluted (in shares)29.9M shares29.9M shares29.9M shares

Compare RETRACTABLE TECHNOLOGIES INC with another company

Corporate structure

RETRACTABLE TECHNOLOGIES INC sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of RETRACTABLE TECHNOLOGIES INC

  • Thomas J. Shaw Filed SCHEDULE 13D/A on RETRACTABLE TECHNOLOGIES INC, latest Aug 29, 2025 (2 filings since Feb 28, 2025)
  • BML Investment Partners, L.P. Filed SC 13G/A on RETRACTABLE TECHNOLOGIES INC, latest Feb 8, 2023 (3 filings since Jan 27, 2022)
  • RETRACTABLE TECHNOLOGIES INC Little Elm, Texas

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What RETRACTABLE TECHNOLOGIES INC reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$134.2M4 Dec 31, 2025$134.6M4 Dec 31, 2024−0.3%
Accumulated depreciation$55.0M4 Dec 31, 2025$47.3M4 Dec 31, 2024+16.4%
Property and equipment, net$79.2M4 Dec 31, 2025$87.3M4 Dec 31, 2024−9.4%
Finance-lease assets$308.0K4 Dec 31, 2025

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$2.6M4 Dec 31, 2025$4.2M4 Dec 31, 2024−38.9%

Inventory

ItemLatestA year beforeChange
Inventory, total$17.2M4 Dec 31, 2025$19.2M4 Dec 31, 2024−10.4%
Raw materials$3.6M4 Dec 31, 2025$4.0M4 Dec 31, 2024−9.9%
Finished goods$13.6M4 Dec 31, 2025$15.2M4 Dec 31, 2024−10.6%

Properties, in its own words

Our headquarters are located at 511 Lobo Lane, on 35 acres, which we own, overlooking Lake Lewisville in Little Elm, Texas. The headquarters are in good condition and houses our administrative offices and manufacturing facility. The manufacturing facility produced approximately 37.4% of the units that were manufactured in 2025. Since 2020, we have significant additional domestic production capacity for some of our products, primarily vaccination syringes and needles associated with the TIA. However, we do not currently have the necessary equipment to produce every product we offer and may continue to rely on our international manufacturers to supply those products, incurring the cost of import tariffs.

A loan in the original principal amount of approximately $4,210,000 is secured by our land and buildings. See Note 9 to our financial statements for more information.

The rest of Item 2

In the opinion of Management, the property and equipment are suitable for their intended use and are adequately covered by an insurance policy.

Item 2 of the 10-K filed Mar 27, 2026.3

Leadership

Who has led RETRACTABLE TECHNOLOGIES INC, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Thomas J. Shaw2006–now

President

  1. Thomas J. Shaw2006–now

Chief financial officer

  1. John W. Fort Iii.2019–2022
2010201520202025
Board members and other officers (13)

Timeline

  1. Sep 30, 20268-K Other events24
  2. Aug 14, 20268-K Other events25
  3. Jun 30, 20268-K Other events26
  4. May 15, 20268-K Other events27
  5. May 13, 20268-K Shareholder vote28
  6. Apr 10, 20268-K Other events29
  7. Mar 27, 20268-K Other events30
  8. Dec 30, 20258-K Other events31
  9. Nov 14, 20258-K Other events32
  10. Sep 30, 20258-K Other events33
  11. Aug 14, 20258-K Other events34
  12. Jul 23, 20258-K Other events35
  13. Nov 13, 2006New chief executive Thomas J. Shaw becomes CEO12

Calendar

Coming up

  1. Nov 13, 2026Reports results for the quarter ending Sep/202636

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

253 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 51 major events, 167 insider forms, 5 large holders, 10 other. The latest 20:

  1. Sep 30, 20268-K EDGAR
  2. Aug 14, 20268-K EDGAR
  3. Aug 14, 202610-Q EDGAR
  4. Jun 30, 20268-K EDGAR
  5. May 15, 20268-K EDGAR
  6. May 15, 202610-Q EDGAR
  7. May 13, 20268-K EDGAR
  8. Apr 10, 20268-K EDGAR
  9. Mar 27, 20268-K EDGAR
  10. Mar 27, 202610-K EDGAR
  11. Mar 27, 2026DEFA14A EDGAR
  12. Mar 27, 2026DEF 14A EDGAR
  13. Dec 30, 20258-K EDGAR
  14. Nov 17, 20254 EDGAR
  15. Nov 14, 20258-K EDGAR
  16. Nov 14, 202510-Q EDGAR
  17. Nov 13, 20254 EDGAR
  18. Nov 6, 20254 EDGAR
  19. Oct 31, 20254 EDGAR
  20. Oct 29, 20254 EDGAR

The 253 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

212 open-market trades by officers, directors and large owners since October 2021: 208 buys and 4 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Nov 14, 2025SHAW THOMAS JPRESIDENT AND CEOBuy5,731$0.77$4.4KForm 4
Nov 11, 2025SHAW THOMAS JPRESIDENT AND CEOBuy100$0.81$81Form 4
Nov 5, 2025SHAW THOMAS JPRESIDENT AND CEOBuy7,500$0.83$6.2KForm 4
Oct 30, 2025SHAW THOMAS JPRESIDENT AND CEOBuy15,000$0.86$12.9KForm 4
Oct 28, 2025SHAW THOMAS JPRESIDENT AND CEOBuy35,000$0.92$32.2KForm 4
Oct 27, 2025SHAW THOMAS JPRESIDENT AND CEOBuy34,506$0.94$32.4KForm 4
Oct 23, 2025SHAW THOMAS JPRESIDENT AND CEOBuy356$0.95$338Form 4
Oct 22, 2025SHAW THOMAS JPRESIDENT AND CEOBuy10,000$0.96$9.6KForm 4
Oct 14, 2025SHAW THOMAS JPRESIDENT AND CEOBuy14,204$0.93$13.2KForm 4
Oct 8, 2025SHAW THOMAS JPRESIDENT AND CEOBuy30,000$0.92$27.6KForm 4
Sep 29, 2025SHAW THOMAS JPRESIDENT AND CEOBuy5,000$0.82$4.1KForm 4
Sep 24, 2025SHAW THOMAS JPRESIDENT AND CEOBuy17,500$0.80$14.0KForm 4
Sep 23, 2025SHAW THOMAS JPRESIDENT AND CEOBuy2,500$0.82$2.0KForm 4
Sep 3, 2025SHAW THOMAS JPRESIDENT AND CEOBuy3,000$0.78$2.3KForm 4
Sep 2, 2025SHAW THOMAS JPRESIDENT AND CEOBuy5,500$0.80$4.4KForm 4
Aug 19, 2025SHAW THOMAS JPRESIDENT AND CEOBuy9,042$0.80$7.2KForm 4
Aug 18, 2025SHAW THOMAS JPRESIDENT AND CEOBuy32,935$0.80$26.3KForm 4
Aug 15, 2025SHAW THOMAS JPRESIDENT AND CEOBuy10,980$0.79$8.7KForm 4
Aug 14, 2025SHAW THOMAS JPRESIDENT AND CEOBuy3,103$0.79$2.5KForm 4
Aug 13, 2025SHAW THOMAS JPRESIDENT AND CEOBuy3,983$0.80$3.2KForm 4

All 212 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

YearExecutiveAgeSalaryTotal pay
2025(principal executive officer)$1.2M$1.2M39
2025General Counsel$400.0K$410.5K39
2025(principal financial officer,$300.0K$310.0K39
2025Kevin McGlinchey$275.0K$292.5K39
2025Vice President of Clinical Affairs$198.4K$203.9K39
2024President and CEO$1.2M$1.2M39
2024Vice President,$400.0K$410.4K39
2024Vice PresidentCFO$300.0K$309.0K39
2024Vice President of Clinical Affairs$198.4K$203.9K39
2024Director of Operations$188.0K$194.2K39
2023Thomas J. Shaw$1.1M$1.1M39
2023Michele M. Larios$400.0K$405.5K39
2023John W. Fort III$300.0K$309.3K39
2023Kathryn M. Duesman$198.4K$211.0K39
2023Lawrence G. Salerno$188.0K$196.1K39

Funding

Where the company's money came from, by calendar year: private offerings filed with the SEC, federal grants, loans, contracts and other assistance from USAspending.gov, and PPP loans from the SBA. Each bar links to the records below.

Money received by year$1.4M 2020–2020
Money received by yearMoney received by year, 2020–2020: $1.4M in all. PPP loans $1.4M.$0$500K$1M$1.5M2020 · PPP loans: $1.4M2020
Figures by year
YearPPP loansTotal
2020$1.4M$1.4M

PPP loans

Paycheck Protection Program loans of $150,000 and up, approved April 2020 to July 2021, from the SBA40. Matched to this company by name and state.

  1. Apr 9, 2020$1.4M PPP loan (first draw) from Independent Bank d/b/a Independent Financial40To RETRACTABLE TECHNOLOGIES, INC., Little Elm TX; $1.4M forgiven May 13, 2021

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 32. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Vanguard Capital Management LLC581,736$418.9K0.0%No change
Eversept Partners, LP580,919$418.3K0.0%No change
Renaissance Technologies LLC441,407$317.8K0.0%+37,400
BlackRock, Inc.241,121$173.6K0.0%−1
Geode Capital Management, LLC121,005$87.1K0.0%−28,443
Bridgeway Capital Management, LLC88,543$63.8K0.0%No change
Citadel Advisors LLC87,333$62.9K0.0%New
Vanguard Fiduciary Trust Co85,260$61.4K0.0%No change
Susquehanna International Group, Llp78,857$56.8K0.0%+45,997
State Street Corp59,796$43.1K0.0%No change
WealthTrust Axiom LLC51,333$37.0K0.0%−1,500
LPL Financial LLC47,566$34.2K0.0%−3,000
Avidian Wealth Enterprises, LLC30,800$22.2K0.0%No change
Northern Trust Corp28,444$20.5K0.0%No change
PFG Investments, LLC26,250$18.9K0.0%No change
XTX Topco Ltd23,218$16.7K0.0%+2,948
Frisch Financial Group, Inc.19,000$13.7K0.0%No change
Pasadena Private Wealth, LLC10,400$7.5K0.0%New
Jones Financial Companies Lllp6,400$4.5K0.0%No change
Vanguard Global Advisers, LLC5,813$4.2K0.0%No change
UBS Group AG4,339$3.1K0.0%+2,638
Morgan Stanley3,530$2.5K0.0%No change
Tower Research Capital LLC (TRC)2,638$1.9K0.0%New
Rockefeller Capital Management L.P.2,500$1.8K0.0%No change
Performa Ltd (US), LLC1,750$1.3K0.0%No change

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How RETRACTABLE TECHNOLOGIES INC is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARRETRACTABLE TECHNOLOGIES INC1
  • CIK0000946563
  • Employer ID (EIN)75-25997623
  • Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; not a shell company3
  • Incorporated inTexas3
  • Fiscal year endsDecember 311
  • Industry code (SIC)3841 Surgical & Medical Instruments & Apparatus1
  • SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance1
  • Business address511 Lobo Lane, Little Elm, TX 75068-00091
  • Phone97229410101
  • Shares outstanding29,937,159 as of Aug 1, 202610
  • Public float$8.1M as of Jun 30, 20253
  • AuditorBaker Tilly US, LLP, Dallas, TX PCAOB ID 23; no auditor attestation of internal control over financial reporting3
  • On EDGAR sinceJun 23, 20001
  • Filings1,130 in all: 4 (588), 8-K (267), 10-Q (65), DEF 14A (28), DEFA14A (25), 10-K (21), SC 13G/A (21), 10QSB (13)1
    All 38 form types

    SC 13D/A (11), 3 (9), UPLOAD (9), CORRESP (7), 4/A (6), SC 13G (5), PRE 14A (4), S-8 POS (4), SB-2/A (4), SC TO-I/A (4), 10-K/A (3), 10KSB (3), 10SB12G/A (3), 5 (3), S-8 (3), SC TO-C (3), 10-Q/A (2), 10KSB/A (2), 10KSB40 (2), POS AM (2), SC 13D (2), SC TO-I (2), SCHEDULE 13D/A (2), 10SB12G (1), 144 (1), 3/A (1), 8-A12B (1), NT 10-Q (1), REGDEX (1), SB-2 (1)

  • Latest filingsAnnual report (10-K) Mar 27, 2026
    Quarterly report (10-Q) Aug 14, 2026
    Proxy statement (DEF 14A) Mar 27, 2026
    Latest 8-K (8-K) Sep 30, 2026

Securities registered for trading

ClassSymbolExchange
Common StockRVPNYSE American LLC

From the cover page of the 10-K filed Mar 27, 2026 (Section 12(b) of the Exchange Act).3

Risk factors and legal proceedings

Legal proceedings

As of March 9, 2026, we were not a party to or subject to any material legal proceedings.

The opening of Item 3, Legal Proceedings.3

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
    SEC EDGAROther events
  25. 25
    SEC EDGAROther events
  26. 26
    SEC EDGAROther events
  27. 27
    SEC EDGAROther events
  28. 28
  29. 29
    SEC EDGAROther events
  30. 30
    SEC EDGAROther events
  31. 31
    SEC EDGAROther events
  32. 32
    SEC EDGAROther events
  33. 33
    SEC EDGAROther events
  34. 34
    SEC EDGAROther events
  35. 35
    SEC EDGAROther events
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40